Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InSite Visions Signs Essex to Market AzaSite® in China

publication date: May 30, 2008

InSite Vision Incorporated of Alameda, CA has out-licensed to Essex Bio-Technology Limited the China rights for AzaSite® (azithromycin ophthalmic solution) 1%, an antiseptic eye drop. Essex will be responsible for securing SFDA approval of the product as a treatment for ocular bacterial infection. Essex is listed on the Growth Enterprise Market (GEM) of the Hong Kong Exchange. More details...

Stock Symbols: (AMEX: ISV) (HK: 8151)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital